Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Am Heart Assoc
Main Authors: Pol, Tymon, Held, Claes, Westerbergh, Johan, Lindbäck, Johan, Alexander, John H., Alings, Marco, Erol, Cetin, Goto, Shinya, Halvorsen, Sigrun, Huber, Kurt, Hanna, Michael, Lopes, Renato D., Ruzyllo, Witold, Granger, Christopher B., Hijazi, Ziad
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5850246/
https://ncbi.nlm.nih.gov/pubmed/29419390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.007444
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki